ArticleOncology research2026
Detection of Prostate Carcinoma in an Asymptomatic Individual Initiated by an Immunological Biopsy-A Case Report.
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With a total of 1.46 million new cases and 396,792 deaths in 2022, prostate cancer is a major medical challenge around the world. Detecting and treating cancer at earlier, preferably localized stages can significantly increase survival rates. Here, a novel blood-based cancer screening as a pre-test in combination with targeted MRI imaging enabled the early diagnosis of prostate cancer. Case Description: We present the case of a 64-year-old man who participated in a prospective, interventional, multicenter cancer screening study where an immunological biopsy-based technique served as a part of a novel screening technique. This immunology technique represents a blood test exploiting two biomarkers, which may allow for the identification of individuals at an early stage of tumor development. Due to the elevated biomarker levels of Transketolase-like protein 1 (TKTL1) and Apoptoic-associated cell population 10 (Apo10), magnetic resonance imaging (MRI) was indicated for further clarification. A multiparametric MRI of the pelvis/prostate revealed an enlarged prostate gland and several suspicious lesions classified as Prostate Imaging Reporting and Data System (PI-RADS) 4 and PI-RADS 5. In further assessments, both lesions were categorized as an acinar adenocarcinoma of the prostate (Gleason Score 6, International Society of Urological Pathology (ISUP) 1, no perineural infiltration). After surgical resection, the tumor was classified histopathologically as an adenocarcinoma, pT2c pN0 (0/7), L0, V0, Pn1, R0, Gleason score 7a, ISUP 2. Conclusions: The combination of the TKTL1/Apo10 blood test and subsequent imaging made it possible to detect a developing prostate carcinoma in a localized stage. All in all, this case report proves not just the ability but also the potential of the TKTL1/Apo10 blood test for early detection of (pre-)malignant lesions, which still present with a promising prospect for a cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.